BioShuttle™ is a groundbreaking delivery technology that enhances the absorption and effectiveness of active ingredients. By leveraging natural processes, BioShuttle™ safely transports compounds across the skin and can even reach the brain. BioShuttle™ is a safe, stable, and cost-effective solution for optimizing ingredient delivery.
Encapsulates active ingredients in stable, biocompatible nanoparticles for rapid delivery to target tissues.
Minimizes systemic exposure, enhancing safety profile of APIs.
Delivers APIs to the brain via the sinus, creating opportunities to treat intractable neurological disorders.
Target promising API candidates that were cancelled due to poor efficacy or adverse effects.
Incorporate candidate APIs to enhance bioavailability, limit whole-body exposure and reduce dosing.
Create new revenue streams from previously abandoned assets.
BioShuttle™'s stabilized liposomes remain stable for up to two years at room temperature, far surpassing traditional liposomes.
Minimal added cost per dose compared to other delivery technologies that can increase costs over 100-fold.
Eliminates time-consuming bottlenecks in formulation development.
Market-ready products can be developed in as little as 2 months, compared to the industry standard of 2+ years.
Streamlined development minimizes resource expenditure, reducing costs and increasing profitability.
Lipotope’s nasal formulation for weight management is designed to support healthy metabolism, balanced energy levels, and mindful eating habits. By leveraging advanced delivery technology, this formulation helps promote a feeling of fullness and encourages wellness-focused nutrition.
In an internal study, participants reported:
Unlike traditional weight management options, this nasal formulation is non-invasive, easy to use, and designed for long-term wellness support. It is expected to launch in the UK market in 2025.
Lipotope's Pain Relief Topical Cream addresses various pain conditions, including arthritis, muscle aches, neuropathic pain, and chronic pain. Its natural ingredients reduce inflammation, block pain signals, and promote healing. Studies showed significant pain reduction, improved mobility, and reduced use of oral medications without adverse effects. The pain product is being introduced to the US in February of 2025 and the European and Australian markets in Q3, 2025.
Lipotope has developed a topical formulation whose active ingredients promote lubrication, comfort, and intimate health. The cream is designed to address common challenges faced by post-menopausal women, such as vaginal dryness, discomfort, and decreased libido. Compared to traditional delivery modalities for the API, BioShuttle™-Intimacy reduces dosing and dramatically speeds the onset of action. The time to effect is changed from a week to less than an hour, making the act of intimacy less of a planned event for postmenopausal women. The product is planned for launch in the US in Q3 of 2025.
Lipotope’s Nasal Spray is designed to support a sense of calm and relaxation, making it easier to unwind before bedtime. Participants in our internal study shared that they felt more at ease and refreshed after incorporating it into their nighttime routine. The formula is non-habit forming and designed to encourage a deeper, more refreshing sleep without grogginess. Planned introduction in the US market in 2025.
Lipotope's topical athletic performance formulation can be administered prior to or after endurance-based or strenuous exercise. When used prior to endurance events, performance is enhanced by approximately 10% for amateur athletes. A further benefit is that DOMS (Delayed Onset Muscle Soreness) is either eliminated or significantly reduced. Planned introduction in the US market in 2025.
Partner to distribute Lipotope's existing formulations.
Develop new formulations using the BioShuttle™ delivery platform.
Unlock potential of existing APIs and create groundbreaking formulations.
Lipotope is actively partnering with global innovators to develop and deliver breakthrough formulations using the BioShuttle™ delivery platform. Current projects include:
A confidential Turkish pharmaceutical partner is co-developing a nasal-delivery formulation of a generic compound shown in preclinical studies to halt and reverse the progression of Alzheimer's and Dementia. Animal studies are scheduled for Q3 2025, with a targeted international release in 2026, pending regulatory clearance.
We are working with partners across the U.S., Europe, and Asia on three topical anti-aging formulations targeting visible signs of aging:
All three prototypes are in development and will be ready for testing later in 2025.
Lipotope continues to explore new collaborations in therapeutic and wellness categories where the BioShuttle™ platform can offer transformative impact. Contact us to discuss partnership opportunities at info@lipotope.net.
BioShuttle™